Calcium Alpha-Ketoglutarate for Health & Longevity

Evidence Review created on 05/02/2026 using AI4L / Opus 4.7

Also known as: CaAKG, Ca-AKG, Ca-α-KG, Calcium Alpha-Ketoglutaric Acid, Calcium 2-Oxoglutarate

Motivation

Calcium alpha-ketoglutarate is the calcium salt of a small molecule the body produces naturally as part of the central energy-generating cycle in every cell. Because alpha-ketoglutarate sits at a metabolic crossroads, influencing energy production, the inflammatory tone of the body, and how genes are switched on and off, it has attracted growing interest as a longevity supplement.

The body’s own alpha-ketoglutarate levels fall sharply with age, and this decline has been linked to lower cellular energy, rising chronic inflammation, and weakening of bone and muscle. Animal work has shown that supplementation can extend healthy lifespan, reduce frailty, and rejuvenate aged stem cells in mice. Early human work in middle-aged adults using a measure of biological age is the first attempt to test whether these effects translate to people.

This review examines the current evidence for calcium alpha-ketoglutarate as a longevity-oriented supplement, including its proposed benefits, known risks, modifying factors, and practical considerations for adults focused on healthspan.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Calcium alpha-ketoglutarate

A reference page covering calcium alpha-ketoglutarate’s chemistry as the divalent calcium salt of 2-oxoglutaric acid, its role in the TCA cycle (tricarboxylic acid cycle, also called the Krebs cycle, the central pathway by which cells generate energy from food), preclinical evidence for lifespan extension in worms, flies, and mice, and clinical use in chronic kidney disease for phosphate binding.

Examine

Alpha-Ketoglutarate

An evidence-based reference covering AKG’s mechanism as a Krebs-cycle intermediate, its role in muscle protein synthesis and amino acid formation, dosing in clinical research (3.6–6 g), and a summary of the Rejuvant biological-age study reporting an average 8-year reduction in DNA methylation age (a measure of biological age based on patterns of chemical tags on DNA).

ConsumerLab

No dedicated ConsumerLab page exists for calcium alpha-ketoglutarate as a standalone supplement.

Systematic Reviews

No systematic reviews or meta-analyses for Calcium Alpha-Ketoglutarate were found on PubMed as of 05/02/2026.

Mechanism of Action

Calcium alpha-ketoglutarate is the calcium salt of alpha-ketoglutaric acid (also called 2-oxoglutarate), an intermediate in the TCA cycle. Once absorbed, the calcium dissociates and free alpha-ketoglutarate enters multiple regulatory pathways relevant to aging.

Energy metabolism: Alpha-ketoglutarate is a substrate for the TCA cycle, supporting ATP (adenosine triphosphate, the cell’s primary energy currency) generation. Endogenous AKG levels decline approximately 10-fold between adolescence and old age, paralleling reduced mitochondrial efficiency.
Epigenetic regulation: AKG is an obligatory cofactor for a class of enzymes called 2-oxoglutarate-dependent dioxygenases, which include the TET enzymes (ten-eleven translocation enzymes that demethylate DNA) and the JmjC histone demethylases (Jumonji C-domain enzymes that remove methyl groups from histone proteins). Through these enzymes, AKG promotes DNA and histone demethylation patterns associated with younger biological age.
mTOR inhibition: AKG binds and inhibits ATP synthase and downregulates mTOR signaling, partially mimicking caloric restriction without dietary intake reduction. Reduced mTOR activity is one of the most replicated longevity-extending interventions across species.
AMPK activation: Indirect AMPK (AMP-activated protein kinase, a master regulator of cellular energy balance) activation contributes to autophagy promotion and metabolic efficiency.
Anti-inflammatory effect: In the Buck Institute mouse study, dietary CaAKG induced systemic IL-10, an anti-inflammatory cytokine, and reduced multiple pro-inflammatory cytokines associated with “inflammaging” (the chronic, low-grade inflammation that develops with aging).
Stem cell maintenance: AKG supports proliferation and function of bone marrow mesenchymal stromal cells, muscle stem cells, and hematopoietic stem cells, in part by maintaining low H3K9me3 and H3K27me3 (repressive histone marks that accumulate with age).
Nitrogen and ammonia metabolism: AKG accepts amino groups in transamination reactions to form glutamate and glutamine, scavenging ammonia and supporting amino acid synthesis.

A competing mechanistic interpretation, articulated by Bayliak and Lushchak (2021) and others, frames AKG as a mild pro-oxidant that triggers hormetic adaptation rather than acting as a pure antioxidant. Under this view, the longevity signal arises from a transient stress response that upregulates endogenous antioxidant defenses, rather than from direct free-radical neutralization.

Key pharmacological properties:

Half-life: Alpha-ketoglutarate has a short plasma half-life (estimated under 1 hour), which is the rationale behind sustained-release formulations used in current human trials.
Selectivity: Non-selective; AKG participates broadly in metabolic, epigenetic, and signaling pathways rather than acting on a single receptor.
Tissue distribution: Distributed broadly across tissues; intracellular AKG concentrations are tightly regulated and vary by tissue.
Metabolism: Endogenously synthesized and consumed continuously within the TCA cycle. Not metabolized by CYP450 (cytochrome P450, the family of liver enzymes that metabolize most drugs) enzymes; ingested AKG is rapidly catabolized through normal mitochondrial pathways.

Historical Context & Evolution

Alpha-ketoglutarate was first identified in the 1930s as a TCA-cycle intermediate following Hans Krebs’ elucidation of the citric-acid cycle, work that earned him the 1953 Nobel Prize in Physiology or Medicine. Its early therapeutic applications were unrelated to aging: AKG was used in nutritional support after surgery, burns, and trauma in the 1980s and 1990s, and as a phosphate binder in chronic kidney disease.

The shift toward longevity began in 2014 when Chin et al. (Nature) showed that AKG extended lifespan in C. elegans by approximately 50% via ATP-synthase inhibition and TOR-pathway downregulation. Drosophila lifespan extension followed. Interest accelerated dramatically with the Buck Institute’s 2020 study (Asadi Shahmirzadi et al., Cell Metabolism) showing that calcium AKG extended healthspan and reduced frailty in aging mice through anti-inflammatory mechanisms.

The first human-relevant signal came in 2021 from a retrospective analysis (Demidenko et al., 2021, Aging) of 42 individuals taking Rejuvant, an AKG-based formulation, for an average of 7 months: DNA-methylation biological age fell by an average of 8 years versus baseline. This trial had no placebo arm and was sponsored by the supplement’s manufacturer, limitations that have shaped subsequent research design. The ongoing ABLE trial (Sandalova et al., 2023) is the first prospective, double-blind, placebo-controlled human RCT (randomized controlled trial, the gold-standard study design that randomly assigns participants to treatment or placebo) of sustained-release CaAKG in middle-aged adults with elevated DNA-methylation age, and is the most important pending data point for the human translation question.

The narrative around AKG has not been “debunked” or “discredited”; rather, the field is still gathering controlled human evidence to determine whether the strong preclinical signal will hold up in rigorous human trials.

Expected Benefits

A dedicated search for the complete benefit profile of calcium alpha-ketoglutarate was performed using PubMed, clinical trial databases, and expert commentary from priority sources.

High 🟩 🟩 🟩

No High-evidence benefits claimable for CaAKG as a longevity intervention in humans as of this review.

Medium 🟩 🟩

Reduction in DNA Methylation Biological Age

The Demidenko et al. (2021) retrospective analysis of 42 adults taking Rejuvant (a sustained-release CaAKG plus vitamin formulation) for an average of 7 months reported an average 8-year reduction in DNA methylation age measured by the TruAge clock. The proposed mechanism is restoration of AKG-dependent demethylase activity, which corrects age-associated hypermethylation patterns. The study lacked a placebo arm, was funded by the manufacturer, and used a single epigenetic clock; the larger ABLE placebo-controlled trial in middle-aged adults is currently the most important confirmatory data point and remains pending.

Magnitude: Average 8-year reduction in TruAge DNA methylation age over 4–10 months in a single open-label study; not yet replicated in placebo-controlled conditions.

Low 🟩

Frailty Reduction in Aging ⚠️ Conflicted

Asadi Shahmirzadi et al. (2020) found dietary CaAKG reduced age-related frailty in mice by over 40% and compressed the period of late-life morbidity. The mechanism is anti-inflammatory: dietary AKG induced IL-10 and reduced pro-inflammatory cytokines. The conflict in the evidence base is between strong, replicated rodent data showing meaningful frailty reduction and a competing interpretation that questions translational validity: short rodent lifespan, dose-equivalence uncertainties, and the absence of any completed human RCT showing frailty reduction make some reviewers (including Bayliak and Lushchak 2021) cautious that the mouse signal will hold up in humans. Translational support comes from the parallel decline of endogenous AKG with age in humans and the ABLE trial’s inclusion of frailty-relevant secondary endpoints (handgrip, leg strength, aerobic capacity), but no completed human RCT has yet shown frailty reduction.

Magnitude: ~40% frailty reduction in mice; no quantified frailty effect in humans yet.

Improvement in Markers of Bone Health

Wang et al. (2020, Nature Communications) demonstrated that AKG supplementation increased bone mass and accelerated bone regeneration in aged mice by reducing repressive histone methylation marks (H3K9me3 and H3K27me3) in mesenchymal stem cells, restoring osteogenic potential. Independent clinical work has shown that AKG salts (including CaAKG) lower elevated parathyroid hormone and improve calcium-phosphate balance in chronic kidney disease, providing indirect support for bone benefit. Direct human bone-density RCTs in healthy aging populations are absent.

Magnitude: Bone mass increase of 30–50% in aged mouse models; PTH (parathyroid hormone, the hormone that regulates calcium balance) normalization at 4.5 g/day in CKD (chronic kidney disease); no quantified bone density change in healthy aging humans.

Anti-Inflammatory Effects

Multiple animal studies show CaAKG reduces systemic levels of pro-inflammatory cytokines (TNF-α (tumor necrosis factor alpha), IL-6 (interleukin-6), IL-1β (interleukin-1 beta)) and elevates IL-10. The Asadi Shahmirzadi 2020 study identified IL-10 induction as a primary mechanism for the lifespan effect. Inflammaging is a recognized driver of multiple age-related diseases, making this a plausible upstream mechanism for several other proposed benefits. Human inflammatory marker changes are an explicit ABLE trial secondary endpoint but unpublished as of this review.

Magnitude: Significant cytokine shifts in mouse models; human magnitude not yet quantified.

Speculative 🟨

Lifespan Extension

In mice, CaAKG extended median lifespan by approximately 8–12% in late-life supplementation studies and produced larger lifespan effects in worms (~50%) and flies (~10–15%). No human lifespan data exist or can practically be obtained on a meaningful timescale. The biological-age proxy provides indirect signal but is not a validated mortality endpoint. This benefit remains mechanistically plausible but speculative for humans.

Improved Skin and Tissue Aging

Mechanistic and animal data suggest AKG can support collagen synthesis (via prolyl-hydroxylase activity, which requires AKG as cofactor) and improve fibroblast function. Some industry-sponsored open-label observations report subjective skin improvements, but no controlled human dermatologic trial of CaAKG has been published.

Ovarian Reserve and Reproductive Aging

Wang et al. (2023, Mol Cell Endocrinol) showed AKG supplementation improved ovarian reserve and oocyte quality in aging mice via mitochondrial and oxidative-stress mechanisms. No corresponding human data yet exist; clinical extrapolation is mechanistic.

Cardiac Function in Pressure Overload

An et al. (2021) showed AKG attenuated pressure-overload-induced cardiac dysfunction in mice through enhanced mitophagy. Whether this signal transfers to human heart failure or longevity-relevant cardiac aging is unstudied.

Benefit-Modifying Factors

Genetic polymorphisms: Variants in TET enzymes (TET1, TET2, TET3) and the IDH1/IDH2 (isocitrate dehydrogenase, the enzymes that produce AKG) genes can influence baseline AKG status and demethylase activity, potentially modifying response. Direct pharmacogenomic data on CaAKG response are absent.
Baseline biomarker levels: Demidenko et al. (2021) reported that biologically older participants (greater positive gap between epigenetic and chronological age) showed larger DNA-methylation age reductions, suggesting greater room to benefit when baseline biological age is elevated. Low baseline NAD+ (nicotinamide adenine dinucleotide, a coenzyme that declines with age) status may interact with AKG benefit through shared epigenetic and metabolic effects.
Sex-based differences: The Rejuvant formulation differs by sex (vitamin A for men, vitamin D for women), reflecting different baseline vitamin status; the AKG dose is identical. Animal lifespan studies in mice have generally shown comparable or slightly larger effects in females.
Pre-existing health conditions: Adults with elevated inflammatory markers, age-related frailty, or chronic kidney disease may experience larger benefit because the mechanistic targets (inflammation, mineral metabolism, mitochondrial function) are more dysregulated. Adults already at low biological age relative to chronological age may have less room to benefit.
Age-related considerations: Endogenous AKG falls roughly 10-fold between young adulthood and old age, so older adults at the older end of the target range have the largest potential gradient to restore. Most preclinical longevity studies have been performed in middle-aged or aged animals; effects in younger adults are unstudied and may be smaller.

Potential Risks & Side Effects

A dedicated search for the complete side-effect profile of calcium alpha-ketoglutarate was performed using PubMed, drug reference sources (drugs.com, WebMD), the Rejuvant prescribing information, and expert commentary.

High 🟥 🟥 🟥

No High-severity risks have been documented for CaAKG at standard supplemental doses.

Medium 🟥 🟥

Hypercalcemia at High or Stacked Doses

Each gram of CaAKG provides approximately 100–125 mg of elemental calcium. Standard 1 g/day supplementation is well below daily calcium intake guidelines, but doses of 3–4.5 g/day used in chronic kidney disease research provide 300–500 mg of calcium that adds to dietary intake. When stacked with dairy-rich diets, dedicated calcium supplements, calcium carbonate antacids, or other calcium-containing longevity supplements (e.g., calcium D-glucarate), total elemental calcium can approach or exceed the 2,500 mg/day tolerable upper intake level for adults under 50 (2,000 mg above 50). Hypercalcemia (elevated blood calcium) and risk of vascular calcification become relevant at sustained excess intake, particularly in adults with reduced kidney function.

Magnitude: Approximately 100–125 mg elemental calcium per 1 g CaAKG; clinically meaningful primarily at chronic intakes above 2 g/day or with stacked calcium sources.

Low 🟥

Mild Gastrointestinal Effects

Open-label experience with Rejuvant and chronic kidney disease studies of CaAKG report mild gastrointestinal side effects including nausea, mild diarrhea, abdominal discomfort, and occasional constipation, generally at higher doses or on an empty stomach. These effects are typically self-limiting and dose-dependent.

Magnitude: GI symptoms in approximately 5–10% of users in open-label data; usually mild and resolving with dose reduction or food co-administration.

Theoretical Cancer-Promoting Effects in Specific Tumor Contexts ⚠️ Conflicted

In specific tumor contexts (notably IDH1/IDH2-mutant gliomas and certain leukemias), the relationship between AKG and the oncometabolite 2-hydroxyglutarate (2-HG) is altered. AKG’s role as a tumor suppressor in some contexts and a substrate for oncometabolite production in others creates theoretical concern. Naeini et al. (2023) and others note this complexity. Mainstream oncology has not flagged dietary CaAKG as contraindicated in cancer survivorship, but the field remains unsettled and the mechanistic conflict is not resolved.

Magnitude: Not quantified in available studies; theoretical risk confined to specific tumor genotypes.

Speculative 🟨

Long-Term Safety Beyond 1–2 Years

No long-term human safety data for daily CaAKG supplementation extending beyond 1–2 years exist in the longevity context. Decades of use as ornithine alpha-ketoglutarate in clinical nutrition support a generally favorable safety profile, but the specific salt form, dose, and chronic-use pattern relevant to longevity supplementation are not yet fully characterized.

Drug Interactions Beyond Calcium-Mediated Effects

Beyond the well-characterized calcium-mediated effects on tetracycline, fluoroquinolone, levothyroxine, and bisphosphonate absorption, AKG-specific drug interactions are largely unstudied. Theoretical interactions with mTOR modulators (rapamycin), other epigenetic-acting compounds, and oncology agents acting on IDH/AKG pathways are mechanistically possible but not confirmed.

Risk-Modifying Factors

Genetic polymorphisms: Adults with IDH1 or IDH2 somatic mutations (typically in cancer contexts) handle AKG metabolism differently and may convert AKG-related substrates to oncometabolites. Variants in calcium-handling genes (e.g., CASR, the calcium-sensing receptor) modify hypercalcemia susceptibility.
Baseline biomarker levels: Adults with baseline serum calcium in the upper-normal range, low PTH, or elevated 1,25-dihydroxyvitamin D (active vitamin D) are more susceptible to hypercalcemia from added calcium load. Reduced eGFR (estimated glomerular filtration rate, a measure of kidney function) increases the risk of mineral retention.
Sex-based differences: Postmenopausal women are at higher risk of hypercalciuria (excess calcium in the urine) with calcium supplementation; men are at higher risk of vascular calcification with chronic high calcium intake. The AKG dose-response itself does not appear to differ meaningfully by sex.
Pre-existing health conditions: Chronic kidney disease (especially CKD stage 3 and beyond), primary hyperparathyroidism (overactive parathyroid glands causing elevated blood calcium), sarcoidosis (an inflammatory disease that produces clusters of immune cells called granulomas, often raising blood calcium) or other granulomatous conditions (diseases marked by granuloma formation), history of calcium-oxalate kidney stones, and active or recent malignancy with IDH1/IDH2 mutation alter the risk profile. Coronary artery calcification on imaging is a relative concern for chronic high-calcium intake.
Age-related considerations: Older adults more frequently have undiagnosed reduced kidney function, polypharmacy, and existing vascular calcification, all of which modestly increase the risk profile of supplemental calcium loading. Conversely, the larger benefit gradient from AKG restoration in older adults often offsets this when total calcium intake is monitored.

Key Interactions & Contraindications

Tetracycline antibiotics (doxycycline, minocycline, tetracycline) (caution; reduced antibiotic absorption): Calcium chelates tetracyclines and reduces their bioavailability by 50–80%. Separate CaAKG and tetracycline antibiotic administration by at least 2 hours.
Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin, moxifloxacin) (caution; reduced antibiotic absorption): Calcium reduces fluoroquinolone absorption by 30–50%. Separate by at least 2 hours.
Levothyroxine (caution; reduced thyroid hormone absorption): Calcium reduces levothyroxine absorption. Take levothyroxine with water on an empty stomach and separate from CaAKG by at least 4 hours.
Bisphosphonates (alendronate, risedronate, zoledronate) (caution; reduced bisphosphonate absorption): Calcium binds oral bisphosphonates and reduces absorption substantially. Take bisphosphonates first thing in the morning with plain water and separate from CaAKG by at least 60 minutes.
Calcium channel blockers (amlodipine, diltiazem, verapamil) (theoretical caution; reduced antihypertensive effect): Theoretical attenuation of antihypertensive effect at very high calcium loads. Practical effect at standard CaAKG doses is small.
Iron supplements (caution; reduced iron absorption): Calcium reduces non-heme iron absorption when co-ingested. Separate iron and CaAKG by at least 1 hour, or take CaAKG away from iron-rich meals.
Thiazide diuretics (hydrochlorothiazide, chlorthalidone, indapamide) (caution; additive hypercalcemia risk): Thiazides reduce urinary calcium excretion and can amplify the hypercalcemic effect of supplemental calcium. Monitor serum calcium when stacking.
Calcium-containing supplements and antacids (caution; cumulative calcium load): Calcium D-glucarate, calcium citrate, calcium carbonate, and calcium-containing multivitamins all add to total calcium intake. Total elemental calcium from supplements typically should not exceed 1,000–1,200 mg/day in addition to dietary calcium for adults; lower for those with vascular calcification or kidney disease.
Other AKG salts (ornithine AKG, arginine AKG) (caution; cumulative AKG exposure): Stacking different AKG salt forms is rarely clinically necessary and increases the cumulative dose without proven additive benefit.
mTOR-modulating compounds (rapamycin, sirolimus) (theoretical caution; mechanistic overlap): AKG and rapamycin both downregulate mTOR via different routes; combined effect is mechanistically additive but unstudied. Coordinate with the prescribing clinician if rapamycin is used.
Populations who should avoid or strictly limit CaAKG: Adults with hypercalcemia, primary hyperparathyroidism, granulomatous disease (sarcoidosis, tuberculosis), severe chronic kidney disease (CKD stage 4–5, eGFR <30 mL/min/1.73 m²) without nephrology supervision, active calcium-oxalate kidney stone disease, IDH1/IDH2-mutant active malignancy, pregnancy and lactation (no safety data), and children under 18 (no safety data).

Risk Mitigation Strategies

Track total daily elemental calcium intake: Adding dietary calcium (food labels and intake estimates) plus elemental calcium from CaAKG (~100–125 mg per gram) plus any other calcium-containing supplements, and capping total at ≤1,200 mg/day above 50 years and ≤1,000 mg/day under 50, mitigates hypercalcemia and vascular calcification risk.
Take with food and adequate hydration: Taking CaAKG with a meal and at least 240 mL water reduces gastrointestinal effects (nausea, mild diarrhea, abdominal discomfort) and improves calcium tolerance.
Separate from interacting medications: Spacing CaAKG at least 2 hours from tetracycline and fluoroquinolone antibiotics, 4 hours from levothyroxine, and 60 minutes from bisphosphonates prevents reduced absorption of those drugs.
Establish baseline labs before starting: Checking serum calcium, ionized calcium (if available), 25-hydroxyvitamin D, intact PTH, eGFR, and a calcium-creatinine ratio before initiation establishes individual susceptibility to hypercalcemia and identifies kidney function or parathyroid issues.
Recheck at 3 and 12 months: Repeating serum calcium and eGFR at 3 months and again at 12 months catches drift before it becomes clinically meaningful.
Use sustained-release formulations when available: Sustained-release CaAKG (the form used in the ABLE trial) maintains plasma AKG more stably and is the form for which the most rigorous human evidence is being generated; standard formulations are also acceptable but require more frequent dosing for similar exposure.
Avoid stacking with other calcium-heavy supplements: Avoiding simultaneous calcium D-glucarate, calcium citrate, calcium carbonate antacids, and calcium-fortified foods on the same day prevents inadvertent cumulative loading.
Coordinate with cancer care team if applicable: For adults with current or prior IDH1/IDH2-mutant malignancy, coordinating CaAKG use with the treating oncologist mitigates the theoretical tumor-context risk.
Monitor for kidney stones in susceptible adults: For adults with prior calcium-oxalate stones, monitoring 24-hour urinary calcium and considering alternative non-calcium-containing AKG salts if elevated mitigates stone recurrence risk.

Therapeutic Protocol

A practical protocol for calcium alpha-ketoglutarate as a longevity-oriented supplement, drawing on the Rejuvant retrospective study, the ABLE trial protocol, and commentary from Peter Attia and Brian Kennedy.

Standard dose: 1,000 mg/day of sustained-release CaAKG taken once daily is the dose used in the ongoing ABLE placebo-controlled trial in middle-aged adults. The Rejuvant retrospective study used a similar daily dose. Some protocols use 1,000 mg twice daily (2 g total) following Brian Kennedy’s published commentary.
Alternative dose ranges: Standalone CaAKG capsules from major longevity vendors are typically dosed at 500–1,000 mg per capsule, with practical regimens of 500–2,000 mg/day split between morning and evening.
Best time of day: Morning with breakfast is the standard pattern. Sustained-release formulations are designed for once-daily morning dosing; immediate-release formulations are often split (morning and early evening) to maintain plasma exposure.
Single dose vs. split doses: AKG has a short plasma half-life (under 1 hour), which is why sustained-release formulations are preferred for single-daily dosing. With immediate-release CaAKG, splitting the daily dose into two administrations roughly 8–10 hours apart provides more uniform exposure.
Half-life: Approximately under 1 hour for free AKG in plasma; sustained-release formulations extend functional exposure across a 6–12 hour window.
Genetic polymorphisms: No validated CaAKG pharmacogenomic protocols exist for variants such as APOE4 (a common variant of the apolipoprotein E gene linked to cardiovascular and Alzheimer’s risk), MTHFR (methylenetetrahydrofolate reductase, an enzyme central to folate and methylation metabolism), or COMT (catechol-O-methyltransferase, an enzyme that breaks down stress neurotransmitters such as dopamine). Adults with documented IDH1/IDH2 somatic mutations (typically known from prior cancer workup) should coordinate use with their oncology team. Variants in calcium-handling genes modestly modify hypercalcemia susceptibility but do not require routine genotyping.
Sex-based differences: Identical AKG doses are used for men and women in the published literature. Rejuvant formulations differ in vitamin co-content (vitamin A for men, vitamin D for women) reflecting baseline status differences, not AKG response.
Age-related considerations: Adults at the older end of the target range often start at 500 mg/day for the first 4 weeks before titrating to 1,000 mg/day, accounting for higher prevalence of reduced kidney function and polypharmacy. The benefit gradient from endogenous AKG decline is greatest in older adults.
Baseline biomarker considerations: Adults with baseline serum calcium near the upper limit (≥10.0 mg/dL), eGFR <60 mL/min/1.73 m², or elevated PTH typically reduce dose to 500 mg/day or use non-calcium-containing AKG forms (e.g., disodium AKG, arginine AKG) to avoid cumulative calcium load.
Pre-existing condition adjustments: Adults with a history of calcium-oxalate kidney stones, granulomatous disease, or chronic kidney disease beyond stage 3 typically pursue specialist supervision or non-calcium AKG forms. Adults with a history of IDH1/IDH2-mutant malignancy coordinate with the oncology team.
Stacking considerations: Brian Kennedy and several longevity-oriented practitioners discuss CaAKG within a stack that may include vitamin D, omega-3, and other geroprotectors; total elemental calcium across the stack is typically capped at 1,000–1,200 mg/day from supplements.

Discontinuation & Cycling

Duration of use: CaAKG is typically used long-term as a daily supplement. The longevity rationale assumes sustained exposure; the largest published human cohort had used Rejuvant for an average of 7 months.
Withdrawal effects: No characterized withdrawal syndrome exists. AKG is endogenously produced, and discontinuation simply returns plasma AKG to baseline over hours to days.
Tapering protocol: Tapering is not required from a physiological perspective. Some protocols halve the dose for 2 weeks before stopping to allow re-adjustment of any concomitant calcium intake.
Cycling: Cycling is not formally recommended. The mechanistic case for daily continuous use (ongoing demethylase cofactor support, inflammation suppression) outweighs the case for intermittent dosing, although some practitioners use 5-days-on/2-days-off patterns to limit cumulative calcium load.

Sourcing and Quality

Form and standardization: Calcium alpha-ketoglutarate is the form with the most preclinical and human longevity research support. Sustained-release formulations are the form used in the ABLE clinical trial. Capsules typically contain 500 mg or 1,000 mg of CaAKG per dose. Alternative non-calcium AKG salts (disodium AKG, arginine AKG, ornithine AKG) are available for adults wishing to limit calcium load.
Third-party testing: Choose products with USP (United States Pharmacopeia, a non-profit setting drug and supplement quality standards), NSF (NSF International, an independent product testing and certification organization), or Informed Choice/Informed Sport certification to verify label accuracy and absence of contaminants. CaAKG is a relatively pure compound, but heavy-metal contamination from calcium sourcing remains a quality concern.
Reputable brands: Ponce de Leon Health (Rejuvant, the formulation studied by Demidenko et al.), DoNotAge (Ca-AKG), ProHealth, NOVOS, and Renue By Science produce CaAKG products commonly used in the longevity community. Sustained-release formulations are branded by select vendors and are the form aligned with the ABLE trial protocol.
What to look for on the label: Stated dose of CaAKG (not just “AKG”), declared elemental calcium per serving, third-party test certificate, batch identifier, and expiration date. AKG is moisture-sensitive and degrades in poorly stored bulk powder; capsules have better shelf stability.
What to avoid: Bulk AKG powder from unverified manufacturers (purity and degradation concerns), arginine AKG products marketed for bodybuilding without longevity-relevant dosing, and combination products that do not disclose AKG mass per dose.
Cost: CaAKG is moderately expensive among longevity supplements; standard 1 g/day regimens cost approximately $30–$60/month; sustained-release Rejuvant runs higher.

Practical Considerations

Time to effect: Cellular AKG levels rise within hours of dosing. Inflammatory and metabolic biomarker shifts in animal studies emerge within 4–8 weeks. DNA-methylation age effects in the Rejuvant retrospective cohort were measured after 4–10 months. Functional outcomes (frailty markers, strength) are expected on a 6–12 month timescale based on the ABLE trial design.
Common pitfalls: Failing to track total daily elemental calcium intake when CaAKG is added to a calcium-containing diet or other supplements, leading to inadvertent cumulative loading; co-administering CaAKG with tetracycline or fluoroquinolone antibiotics, levothyroxine, or bisphosphonates without adequate spacing, reducing the absorption of those medications; using arginine AKG products dosed for bodybuilding rather than CaAKG dosed for longevity; expecting acute symptomatic effects (the intervention is asymptomatic and operates over months); and stopping early when biomarker changes are slow.
Regulatory status: CaAKG is sold in the United States as a dietary supplement and is not regulated as a drug. The U.S. FDA has not approved any AKG product for treatment of aging or any age-related disease. In several European jurisdictions AKG is similarly classified as a food supplement. There are no controlled-substance restrictions.
Cost and accessibility: CaAKG is available globally through online supplement vendors. Sustained-release formulations are less widely distributed than standard immediate-release. Cost is moderate for the longevity supplement category but is non-trivial over years of use.

Interaction with Foundational Habits

Sleep: Indirect interaction. CaAKG has no known direct effect on sleep architecture. Anti-inflammatory and metabolic effects may indirectly support sleep quality in adults with elevated baseline inflammation. No specific timing relative to bedtime is required.
Nutrition: Direct potentiating interaction with a TCA-cycle-supportive diet. CaAKG’s effects are downstream of mitochondrial substrate availability, so adequate B-vitamin status (especially B1, B2, B3, B5), magnesium, and protein intake support the mechanistic pathway. Direct interaction with dietary calcium: cumulative calcium intake should be tracked. Caloric restriction or time-restricted eating may share mTOR-related mechanisms with CaAKG; the combined effect is mechanistically aligned but not clinically quantified.
Exercise: Direct potentiating interaction. Exercise transiently raises endogenous AKG, especially after resistance and high-intensity training; CaAKG supplementation maintains higher baseline AKG availability. Animal data (Wang et al. 2020) show synergistic effects on bone and muscle stem cells when AKG is combined with mechanical loading. Take CaAKG separately from training meals if iron-rich pre-workout foods are involved (calcium can blunt non-heme iron absorption).
Stress management: Indirect interaction via inflammation modulation. Chronic psychological stress drives the same inflammaging pattern that CaAKG opposes; the combined leverage of effective stress management plus CaAKG is mechanistically additive. CaAKG does not directly modulate cortisol or HPA-axis (hypothalamic-pituitary-adrenal axis, the body’s central stress-response system) function in available evidence.

Monitoring Protocol & Defining Success

Baseline assessment should be performed before starting calcium alpha-ketoglutarate, with follow-up at 3 months and then every 6–12 months once stable.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Serum calcium	9.2–10.0 mg/dL	Detects hypercalcemia from cumulative calcium load	Conventional reference 8.6–10.2 mg/dL; functional target avoids upper-range drift; pair with albumin for corrected calcium
Ionized calcium	4.6–5.3 mg/dL	More precise calcium status when albumin is abnormal	Conventional reference 4.5–5.6 mg/dL; preferred over total calcium in adults with low albumin or kidney disease
Intact PTH	20–40 pg/mL	Detects parathyroid response to calcium load	Conventional reference 15–65 pg/mL; functional target identifies subclinical hyperparathyroidism early
25-hydroxyvitamin D	40–60 ng/mL	Co-regulates calcium absorption	Conventional reference 30–100 ng/mL; functional target supports bone benefit while limiting hypercalcemia risk
eGFR	>75 mL/min/1.73 m²	Identifies reduced kidney function affecting mineral handling	Conventional reference >60 mL/min/1.73 m² is “normal”; below 60 prompts dose reduction or non-calcium AKG forms
Cystatin C	0.5–1.0 mg/L	Sensitive kidney function marker, especially in older adults	Conventional reference 0.5–1.2 mg/L; preferred over creatinine-based eGFR alone in adults with low or high muscle mass
24-hour urinary calcium	100–250 mg/24h	Detects hypercalciuria predisposing to kidney stones	Conventional reference up to 300 mg/24h (men) or 250 mg/24h (women); useful for adults with prior stones
hs-CRP	<1.0 mg/L	Tracks anti-inflammatory benefit	Conventional reference <3.0 mg/L; functional target reflects optimal inflammation status
IL-6	<1.5 pg/mL	Tracks inflammaging marker	Conventional reference varies by lab; trend over time more informative than single value
Biological age (DNA methylation)	Less than chronological age	Tracks the primary outcome from the Rejuvant study	TruAge, GrimAge, PhenoAge, or DunedinPACE clocks; expect slow change measured over months; acknowledge between-clock variability

Qualitative markers:
- Energy and stamina across the day
- Subjective frailty markers (grip impressions, getting up from a chair, stair climbing)
- Recovery from exercise
- Joint comfort and mobility
- Skin appearance and hydration
- Subjective inflammation indicators (morning stiffness, post-meal sluggishness)
- The most informative qualitative marker over months is the trend in stamina and recovery rather than acute day-to-day feel, which CaAKG does not change.

Emerging Research

ABLE: Alpha-ketoglutarate supplementation and BiologicaL agE in middle-aged adults: NCT05706389 — a Phase 2, double-blind, placebo-controlled randomized trial of 1 g/day sustained-release CaAKG versus placebo for 6 months with 3-month follow-up in 120 adults aged 40–60 with elevated DNA-methylation age. The primary endpoint is reduction in DNA methylation age; secondary endpoints include inflammatory and metabolic markers, handgrip and leg strength, arterial stiffness, skin autofluorescence, and aerobic capacity. Protocol publication: Sandalova et al., 2023.
Calcium α-Ketoglutarate (AKG-Ca) in Improving Human Aging: NCT07114536 — a randomized, double-blind, placebo-controlled trial of 30 adults aged 40–75 receiving 2 g/day CaAKG (or starch placebo) for 12 weeks, with change in PhenoAge from baseline to week 12 as the primary endpoint and secondary endpoints including bone calcium content, grip strength, inflammatory markers (TNF-α, IL-6, IL-10), glucose/lipid metabolism, and quality-of-life measures.
Alpha-Ketoglutarate Enhances Geroprotection In Surgery (AEGIS): NCT07031128 — a Phase 4 RCT of 250 patients undergoing coronary artery bypass grafting evaluating alpha-ketoglutarate’s perioperative geroprotective effect, an indirect test of AKG’s effect on aged-tissue resilience.
Reducing Inflammatory Syndrome in Surgery — Colorectal (RISIS-CR): NCT06646809 — a Phase 3 RCT of 80 patients evaluating alpha-ketoglutarate’s anti-inflammatory effect in colorectal cancer surgery, contributing indirect mechanistic data on AKG’s inflammation-modulating effect in humans.
Alpha-Ketoglutarate and Abdominal Aortic Aneurysm: NCT04723888 — an interventional study of 300 patients evaluating whether alpha-ketoglutarate slows aneurysm progression, contributing data on vascular aging endpoints.
Mechanistic muscle stem cell research: Ciuffoli et al., 2024 demonstrated that AKG and glutamine restore impaired muscle regeneration in old mice via PSAT1 (phosphoserine aminotransferase 1, an enzyme in the serine biosynthesis pathway)-driven serine biosynthesis, directly relevant to sarcopenia-prevention applications and supporting future trial designs targeting muscle aging.
Future research areas: Independent replication of the Demidenko et al. (2021) DNA-methylation result in placebo-controlled conditions; head-to-head comparison of CaAKG with non-calcium AKG salts; longer-term (3–5 year) human safety data; examination of AKG response in specific genotypes (TET2 mutation carriers, IDH1/IDH2 polymorphisms); and integration of CaAKG with other geroprotectors (rapamycin, metformin, NAD+ precursors). Published work by Bayliak and Lushchak, 2021 on hormesis-based interpretations of the AKG longevity signal and by Wang et al., 2020 on AKG’s role in age-related bone loss via histone-methylation regulation will continue to shape future trial design.

Conclusion

Calcium alpha-ketoglutarate is a calcium salt of a small molecule the body produces naturally as part of its core energy-generating cycle. Endogenous levels fall sharply with age, and animal studies have shown that restoring this molecule can reduce frailty, lower chronic inflammation, and modestly extend healthy lifespan in mice, with parallel signals in worms and flies. The mechanistic case is well developed and links the compound to several pathways already studied in longevity science, including epigenetic regulation, energy metabolism, and inhibition of growth signaling.

Human evidence is much thinner. The principal data point is a small open-label retrospective study in adults using a commercial alpha-ketoglutarate-vitamin formulation, which reported a notable reduction in biological age but lacked a placebo arm and was sponsored by the supplement’s manufacturer.

For health-focused adults, calcium alpha-ketoglutarate appears generally well tolerated at standard doses, with the main practical consideration being cumulative calcium load when used alongside other calcium sources. The current evidence base sits in the space where preclinical signals are strong, mechanistic rationale is rich, and human data are open-label and sponsor-linked.

Top - Benefits - Risks - Protocol

Calcium Alpha-Ketoglutarate for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Reduction in DNA Methylation Biological Age

Low 🟩

Frailty Reduction in Aging ⚠️ Conflicted

Improvement in Markers of Bone Health

Anti-Inflammatory Effects

Speculative 🟨

Lifespan Extension

Improved Skin and Tissue Aging

Ovarian Reserve and Reproductive Aging

Cardiac Function in Pressure Overload

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Hypercalcemia at High or Stacked Doses

Low 🟥

Mild Gastrointestinal Effects

Theoretical Cancer-Promoting Effects in Specific Tumor Contexts ⚠️ Conflicted

Speculative 🟨

Long-Term Safety Beyond 1–2 Years

Drug Interactions Beyond Calcium-Mediated Effects

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion